Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026

CAMBRIDGE, Mass., Aug. 26, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of US$106....